{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:01Z","timestamp":1786991221679,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jacadv.2025.101604","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T15:18:30Z","timestamp":1739632710000},"page":"101604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Rhythm and Conduction Disorders in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-7714","authenticated-orcid":false,"given":"Charles","family":"Guenancia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lequeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Buiciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Defaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Eicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Galand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-6582","authenticated-orcid":false,"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lellouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Oghina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101604_bib1","first-page":"1065","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.jacadv.2025.101604_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"43","author":"Damy","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib5","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib6","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS)","author":"Garcia-Pavia","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jacadv.2025.101604_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacadv.2025.101604_bib9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.revmed.2022.04.036","volume":"43","author":"Oghina","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jacadv.2025.101604_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101604_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib14","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib15","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacadv.2025.101604_bib17","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacadv.2025.101604_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2025.101604_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib21","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ehf2.13851","article-title":"Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis","volume":"9","author":"Papathanasiou","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib23","article-title":"Atrial fibrillation: better symptom control with rate and rhythm management","volume":"37","author":"Gupta","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jacadv.2025.101604_bib24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/europace\/euz046","volume":"21","author":"Arnar","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacadv.2025.101604_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301753","article-title":"Catheter ablation of atrial arrhythmias in cardiac amyloidosis: impact on heart failure and mortality","volume":"19","author":"Maury","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2025.101604_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hrthm.2019.06.022","article-title":"Catheter ablation of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy","volume":"17","author":"Laredo","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacadv.2025.101604_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(16)31277-6","article-title":"Rhythm control in atrial fibrillation","volume":"388","author":"Piccini","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jacadv.2025.101604_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in Adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib29","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jacc.2020.02.025","article-title":"Atrial fibrillation: JACC council perspectives","volume":"75","author":"Chung","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae155","article-title":"Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia","volume":"26","author":"Kanazawa","year":"2024","journal-title":"Europace"},{"key":"10.1016\/j.jacadv.2025.101604_bib31","author":"Damy"},{"key":"10.1016\/j.jacadv.2025.101604_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2025.101604_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jacadv.2025.101604_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131813","article-title":"Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: a systematic review and meta-analysis","volume":"402","author":"Kang","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacadv.2025.101604_bib37","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101604_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100561","article-title":"Effect of defibrillator on all-cause mortality in patients with cardiac amyloidosis","volume":"2","author":"Al-Sadawi","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2025.101604_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad105","article-title":"Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy","volume":"25","author":"Kawahara","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.jacadv.2025.101604_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","article-title":"Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival","volume":"29","author":"Kharoubi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2025.101604_bib43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ehf2.13663","article-title":"Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis","volume":"9","author":"Fischer","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib45","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101604_bib46","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.hrthm.2023.03.1538","article-title":"2023 HRS\/APHRS\/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure","volume":"20","author":"Chung","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacadv.2025.101604_bib47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.jacadv.2025.101604_bib49","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2023.04.008","article-title":"Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring","volume":"381","author":"Fumagalli","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101604_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101604_bib52","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib53","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101604_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacadv.2025.101604_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.zefq.2022.04.025","article-title":"Reporting guidelines for Delphi techniques in health sciences: a methodological review","volume":"172","author":"Spranger","year":"2022","journal-title":"Z\u00a0Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.jacadv.2025.101604_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead026","article-title":"Adverse outcomes of atrial fibrillation ablation in heart failure patients with and without cardiac amyloidosis: a Nationwide Readmissions Database analysis (2015-2019)","volume":"3","author":"Ullah","year":"2023","journal-title":"Eur Heart J Open"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:34:32Z","timestamp":1780724072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2772963X25000213"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101604","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Rhythm and Conduction Disorders in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101604"}}